{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:55:47Z","timestamp":1761663347962},"reference-count":16,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T00:00:00Z","timestamp":1425513600000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic><jats:bold>Background:<\/jats:bold><\/jats:italic> Patients with acute cardio-embolic stroke from atrial fibrillation (AF) are at risk for recurrence with up to 50% of recurrent stroke occurring within two weeks of the index event. Anti-coagulation with heparinoids within 48 hours of stroke has been shown to increase risk of symptomatic intracranial hemorrhage (ICH) with no clear benefit on early stroke recurrence. <jats:italic><jats:bold>Methods<\/jats:bold>:<\/jats:italic> This study was a retrospective chart review of consecutive patients who were admitted to the stroke service at the Foothills Medical Centre between 2009 and 2011. All patients with an acute stroke with a cardio-embolic etiology and a diagnosis of atrial fibrillation were reviewed. We hypothesized that anti-coagulation within two weeks of stroke, appropriately begun because of a diagnosis of AF, decreased rates of recurrent stroke without causing an increase in rates of symptomatic ICH. <jats:italic><jats:bold>Results:<\/jats:bold><\/jats:italic> Between 2009-2011, 324 patients were identified with cardio-embolic stroke secondary to AF. Within two weeks of stroke onset 61.4% (199\/324) of patients were therapeutic on anti-coagulation. Patients who were anti-coagulated had a smaller median index stroke volume (3.2 ml vs 18.4 ml). Three (0.9%) patients suffered a clinically significant ICH. Recurrent stroke occurred in 11 patients (3.4%) within the two-week period. Therapeutic anti-coagulation within two weeks of initial stroke was associated with a decreased risk of recurrent stroke (RR 0.1, 95% CI 0.03-0.64). <jats:italic><jats:bold>Conclusions:<\/jats:bold><\/jats:italic> Anti-coagulation within two weeks of acute stroke in patients with AF appears to be safe among patients with smaller infarcts and prevents early recurrent infarction.<\/jats:p>","DOI":"10.1017\/cjn.2015.7","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T11:42:36Z","timestamp":1425555756000},"page":"92-95","source":"Crossref","is-referenced-by-count":8,"title":["Early Anti-Coagulation after Ischemic Stroke due to Atrial Fibrillation is Safe and Prevents Recurrent Stroke"],"prefix":"10.1017","volume":"42","author":[{"given":"Christopher","family":"Hahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2015,3,5]]},"reference":[{"key":"S0317167115000074_ref8","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.25.3.684"},{"key":"S0317167115000074_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-011-0178-y"},{"key":"S0317167115000074_ref6","doi-asserted-by":"publisher","DOI":"10.1161\/hs1001.097093"},{"key":"S0317167115000074_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02085-7"},{"key":"S0317167115000074_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)04011-7"},{"key":"S0317167115000074_ref16","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000254600.92975.1f"},{"key":"S0317167115000074_ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"S0317167115000074_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.9.1098"},{"key":"S0317167115000074_ref2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"S0317167115000074_ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.16.1265"},{"key":"S0317167115000074_ref1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"S0317167115000074_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00146-6"},{"key":"S0317167115000074_ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.12.1316"},{"key":"S0317167115000074_ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6569.2011.00588.x"},{"key":"S0317167115000074_ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.22.2901"},{"key":"S0317167115000074_ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000108160"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167115000074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T03:33:10Z","timestamp":1555817590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167115000074\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0317167115000074"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2015.7","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}